amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, announced today the dosing of the first patient in the extension cohort of its ongoing phase I/Ib study evaluating AMC303, amcure’s lead compound. The decision to move into the second part of the clinical trial protocol was based on positive safety and pharmacokinetic data obtained in the dose escalation part and a recommendation by the data safety monitoring board. amcure will present top-line data from the dose-escalation part of the trial in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, October 19-23 in Munich/Germany.
Link:
businesswire.com/news/home/20180806005048/en/amcure-Announces-Patient-Dosed-AMC303-Phase-Ib
No comments:
Post a Comment